Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective.
DNA methylation
epigenetics
histone modifications
lung cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
03
10
2023
revised:
06
11
2023
accepted:
09
11
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Lung cancer, primarily non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), is distinguished by its high prevalence and marked mortality rates. Traditional therapeutic approaches, encompassing chemotherapy, radiation, and targeted therapies, frequently show limited efficacy due to acquired resistance and notable side effects. The objective of this review is to introduce a fresh perspective on the therapeutic strategies for lung cancer, emphasizing interventions targeting the epigenetic alterations often seen in this malignancy. This review presents the most recent advancements in the field, focusing on both past and current clinical trials related to the modulation of methylation patterns using diverse molecular agents. Furthermore, an in-depth analysis of the challenges and advantages of these methylation-modifying drugs will be provided, assessing their efficacy as individual treatments and their potential for synergy when integrated with prevailing therapeutic regimens.
Identifiants
pubmed: 38001653
pii: cancers15225394
doi: 10.3390/cancers15225394
pmc: PMC10670535
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Carcinogenesis. 2010 Jan;31(1):27-36
pubmed: 19752007
Cell. 1993 Sep 24;74(6):957-67
pubmed: 8402885
Breast Cancer Res Treat. 2010 Apr;120(3):581-92
pubmed: 19459041
Cell Biol Int. 2014 Feb;38(2):187-97
pubmed: 24323360
Cancer Sci. 2020 Feb;111(2):561-570
pubmed: 31782583
Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):252-7
pubmed: 18162535
Oncotarget. 2017 Jan 24;8(4):6845-6856
pubmed: 28036263
Nat Rev Genet. 2002 Jun;3(6):415-28
pubmed: 12042769
Anticancer Drugs. 2015 Nov;26(10):1069-77
pubmed: 26317683
Iran J Pharm Res. 2021 Summer;20(3):324-336
pubmed: 34903992
Clin Cancer Res. 2002 May;8(5):1178-84
pubmed: 12006535
Cancers (Basel). 2020 Jun 23;12(6):
pubmed: 32585896
Mol Ther. 2021 May 5;29(5):1758-1771
pubmed: 33571681
Oncogene. 1998 Nov 19;17(20):2669-75
pubmed: 9840931
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Lung Cancer. 2004 Sep;45(3):381-6
pubmed: 15301879
Oncol Rep. 2016 Feb;35(2):887-95
pubmed: 26718483
Nat Rev Mol Cell Biol. 2019 Oct;20(10):642-657
pubmed: 31350521
Int J Oncol. 2001 Aug;19(2):277-81
pubmed: 11445839
Nucleic Acids Res. 2014 Sep;42(15):9908-24
pubmed: 25104022
Nat Rev Clin Oncol. 2020 Feb;17(2):91-107
pubmed: 31570827
Cancer Res. 2006 May 15;66(10):5409-18
pubmed: 16707469
Oncol Rep. 2006 Jan;15(1):187-91
pubmed: 16328054
Clin Ter. 1988 Jun 30;125(6):435-41
pubmed: 2973950
ACS Chem Biol. 2016 Mar 18;11(3):772-781
pubmed: 26598975
J Transl Med. 2022 Dec 26;20(1):620
pubmed: 36572880
Cancers (Basel). 2019 Aug 09;11(8):
pubmed: 31404976
Clin Cancer Res. 2005 May 15;11(10):3862-8
pubmed: 15897587
Annu Rev Physiol. 2015;77:453-74
pubmed: 25668024
Anticancer Res. 2013 Aug;33(8):2989-96
pubmed: 23898051
Cancer Metastasis Rev. 2015 Jun;34(2):229-41
pubmed: 25939322
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
Cancer Lett. 2005 Jul 8;225(1):131-9
pubmed: 15922865
J Cancer Res Clin Oncol. 2016 Sep;142(9):1927-46
pubmed: 27393180
EBioMedicine. 2016 Jun;8:30-39
pubmed: 27428416
N Engl J Med. 2008 Mar 20;358(12):1250-61
pubmed: 18354103
Lung Cancer. 2007 Apr;56(1):115-23
pubmed: 17196704
Eur J Med Chem. 2016 Oct 4;121:451-483
pubmed: 27318122
Cardiovasc Res. 2011 Jun 1;90(3):430-40
pubmed: 21558279
Cancer Cell. 2019 Jul 8;36(1):100-114.e25
pubmed: 31257072
Cell Rep. 2016 Apr 19;15(3):574-587
pubmed: 27068473
Mol Cancer Ther. 2008 Jul;7(7):1923-30
pubmed: 18606719
PLoS One. 2013 Nov 14;8(11):e80730
pubmed: 24244712
Onco Targets Ther. 2019 Dec 12;12:10903-10916
pubmed: 31849494
Drug Des Devel Ther. 2015 Mar 24;9:1785-96
pubmed: 25848215
Eur J Cancer. 2012 Apr;48(6):929-35
pubmed: 22019212
Oncotarget. 2017 Apr 18;8(32):52465-52473
pubmed: 28881744
Science. 2016 Mar 11;351(6278):1214-8
pubmed: 26912360
Science. 2009 Aug 14;325(5942):834-40
pubmed: 19608861
J Cell Biochem. 2011 Oct;112(10):3044-53
pubmed: 21678477
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12754-9
pubmed: 10535995
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32751889
Cancer Lett. 2018 Mar 28;417:152-160
pubmed: 29306016
Sci Rep. 2020 Jan 21;10(1):843
pubmed: 31965001
Epigenomics. 2009 Dec;1(2):239-59
pubmed: 20495664
Nat Rev Dis Primers. 2021 Jan 14;7(1):3
pubmed: 33446664
Int J Cancer. 2008 Jul 1;123(1):8-13
pubmed: 18425818
Int J Mol Sci. 2016 Dec 20;17(12):
pubmed: 27999407
Cold Spring Harb Perspect Biol. 2014 May 01;6(5):a019133
pubmed: 24789823
Histochem Cell Biol. 2021 Jun;155(6):637-653
pubmed: 33974136
Sci Rep. 2017 May 12;7(1):1811
pubmed: 28500316
Dis Markers. 2007;23(1-2):105-12
pubmed: 17325430
J Cell Physiol. 2015 May;230(5):969-81
pubmed: 25336183
Oncotarget. 2017 May 30;8(22):36354-36367
pubmed: 28422739
Cancer. 2007 Dec 15;110(12):2785-92
pubmed: 17960794
Gen Thorac Cardiovasc Surg. 2011 Aug;59(8):527-37
pubmed: 21850578
Bosn J Basic Med Sci. 2021 Aug 01;21(4):386-397
pubmed: 33175673
Genes (Basel). 2018 Dec 14;9(12):
pubmed: 30558227
Cell. 2017 Nov 30;171(6):1284-1300.e21
pubmed: 29195073
Cell Oncol (Dordr). 2019 Dec;42(6):739-756
pubmed: 31396859
PLoS One. 2010 Nov 04;5(11):e13834
pubmed: 21079797
Sci Rep. 2018 Mar 2;8(1):3917
pubmed: 29500455
Int J Mol Sci. 2019 Mar 07;20(5):
pubmed: 30866410
Transl Oncol. 2013 Apr;6(2):197-205
pubmed: 23544172
Cancer Discov. 2011 Dec;1(7):598-607
pubmed: 22586682
Eur J Radiol Open. 2020 Jan 28;7:100210
pubmed: 33102632
Genes (Basel). 2020 Jul 20;11(7):
pubmed: 32698529
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1973;16(3):155-64
pubmed: 4374741
Anticancer Drugs. 2009 Oct;20(9):815-21
pubmed: 19644355
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
PLoS One. 2015 May 11;10(5):e0123369
pubmed: 25961819
Cancer Chemother Pharmacol. 2015 Mar;75(3):475-83
pubmed: 25552401
Cancers (Basel). 2022 Feb 15;14(4):
pubmed: 35205708
Int J Mol Sci. 2021 Oct 28;22(21):
pubmed: 34769131
Int J Cancer. 2003 Aug 10;106(1):45-51
pubmed: 12794755
Cancer Drug Resist. 2019;2:141-160
pubmed: 34322663
Cancers (Basel). 2020 Jul 02;12(7):
pubmed: 32630699
J Biol Chem. 2022 Sep;298(9):102367
pubmed: 35963436
Cold Spring Harb Perspect Med. 2021 Jun 1;11(6):
pubmed: 32900703
Nat Cell Biol. 2018 Dec;20(12):1349-1360
pubmed: 30482943
Transl Res. 2015 Jan;165(1):74-90
pubmed: 24686037
Lung Cancer. 2014 May;84(2):161-7
pubmed: 24636848
Mol Cancer. 2008 Oct 23;7:81
pubmed: 18947422
Annu Rev Med. 2016;67:73-89
pubmed: 26768237
Am J Vet Res. 1970 Oct;31(10):1901-4
pubmed: 5528343
Nat Commun. 2022 Apr 4;13(1):1797
pubmed: 35379845
Oncol Rep. 2013 May;29(5):1975-82
pubmed: 23440266
Cancer Res. 2001 Nov 1;61(21):7959-63
pubmed: 11691819
Lung Cancer. 2017 Jan;103:58-65
pubmed: 28024697
PLoS One. 2012;7(1):e30240
pubmed: 22279574
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6
pubmed: 9751761
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
J Thorac Oncol. 2009 Apr;4(4):522-6
pubmed: 19347984
Sci Rep. 2015 Mar 10;5:8897
pubmed: 25754026
Transl Oncol. 2022 Apr;18:101364
pubmed: 35168143
Biochemistry. 2011 Jun 28;50(25):5566-82
pubmed: 21619050
Mol Cancer. 2020 Apr 27;19(1):79
pubmed: 32340605
Lung. 2009 Nov-Dec;187(6):401-11
pubmed: 19795170
Int J Mol Sci. 2017 Jul 01;18(7):
pubmed: 28671573
Int J Mol Sci. 2020 Jun 28;21(13):
pubmed: 32605217
Cell Rep. 2018 Sep 4;24(10):2643-2657
pubmed: 30184499
Nat Rev Cancer. 2007 Oct;7(10):778-90
pubmed: 17882278
Mol Biol Rep. 2013 Jan;40(1):309-25
pubmed: 23086271